Sagimet Biosciences
SGMT
122 hedge funds and large institutions have $394M invested in Sagimet Biosciences in 2026 Q2 according to their latest regulatory filings, with 58 funds opening new positions, 36 increasing their positions, 10 reducing their positions, and 24 closing their positions.
465% more capital invested
Capital invested by funds: $69.8M → $394M (+$325M)
260% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 10
142% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 24
117.62% more ownership
Funds ownership: 41.71% → 159.33% (+118%)
39% more funds holding
Funds holding: 88 → 122 (+34)
3% more call options, than puts
Call options by funds: $3.53M | Put options by funds: $3.42M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$39.3M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$24.7M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$19.9M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$17M |
| 5 |
CP
Caligan Partners
New York
|
+$17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$5.04M |
| 2 |
D.E. Shaw & Co
New York
|
-$2.65M |
| 3 |
Renaissance Technologies
New York
|
-$1.89M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$1.72M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$980K |
SGMT Hedge Fund Activity: Q2 2026 in Review
122 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in Sagimet Biosciences (SGMT) for Q2 2026, worth a combined $394M — up 465% from $69.8M a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new SGMT positions and 24 closed out — a net gain of 34 holders — while 36 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock, adding an estimated $39.3M. The largest seller was Marshall Wace, exiting entirely with an estimated $5.04M sold.
- 122 institutional investors held Sagimet Biosciences (SGMT) as of Q2 2026, up from 88 in Q1 2026.
- Funds reported $394M of Sagimet Biosciences stock for Q2 2026, up 465% quarter-over-quarter.
- 58 funds opened new Sagimet Biosciences positions in Q2 2026 and 24 closed out, a net change of +34 holders.
- The largest Sagimet Biosciences buyer in Q2 2026 was BlackRock, an estimated $39.3M added.
- The largest Sagimet Biosciences seller in Q2 2026 was Marshall Wace, an estimated $5.04M sold.
Based on aggregated 13F filings for Q2 2026.